Guardant Health, Inc. (NASDAQ:GH) Shares Bought by Two Sigma Advisers LP

Two Sigma Advisers LP lifted its holdings in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 52.7% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,177,300 shares of the company's stock after buying an additional 406,500 shares during the period. Two Sigma Advisers LP owned about 0.95% of Guardant Health worth $27,007,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the business. Cerity Partners LLC grew its position in Guardant Health by 54.6% during the 3rd quarter. Cerity Partners LLC now owns 195,008 shares of the company's stock worth $4,473,000 after acquiring an additional 68,883 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in Guardant Health by 1,282.5% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company's stock worth $28,128,000 after buying an additional 1,137,482 shares during the period. First Light Asset Management LLC raised its stake in shares of Guardant Health by 119.7% in the second quarter. First Light Asset Management LLC now owns 416,967 shares of the company's stock worth $12,042,000 after purchasing an additional 227,202 shares during the last quarter. International Assets Investment Management LLC raised its stake in shares of Guardant Health by 2,193.9% in the third quarter. International Assets Investment Management LLC now owns 10,208 shares of the company's stock worth $2,340,000 after purchasing an additional 9,763 shares during the last quarter. Finally, Sei Investments Co. bought a new position in shares of Guardant Health in the second quarter valued at approximately $831,000. Institutional investors and hedge funds own 92.60% of the company's stock.

Insiders Place Their Bets

In other news, Director Meghan V. Joyce sold 2,896 shares of the business's stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total transaction of $86,590.40. Following the completion of the sale, the director now owns 7,648 shares of the company's stock, valued at $228,675.20. The trade was a 27.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 5.50% of the company's stock.

Guardant Health Price Performance

Shares of NASDAQ GH traded down $0.24 during mid-day trading on Friday, hitting $36.87. 1,567,808 shares of the company's stock traded hands, compared to its average volume of 2,065,089. The company's 50-day moving average is $26.60 and its two-hundred day moving average is $27.76. The company has a debt-to-equity ratio of 16.70, a current ratio of 6.22 and a quick ratio of 5.85. The company has a market capitalization of $4.56 billion, a P/E ratio of -8.70 and a beta of 1.26. Guardant Health, Inc. has a 1 year low of $15.81 and a 1 year high of $38.53.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.33). Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The firm had revenue of $191.48 million during the quarter, compared to analysts' expectations of $170.49 million. During the same period last year, the company earned ($0.73) earnings per share. The business's revenue for the quarter was up 33.9% compared to the same quarter last year. On average, equities analysts anticipate that Guardant Health, Inc. will post -3.44 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on GH shares. Sanford C. Bernstein reduced their price objective on Guardant Health from $40.00 to $35.00 and set an "outperform" rating for the company in a report on Wednesday, October 30th. Piper Sandler raised their price target on Guardant Health from $30.00 to $34.00 and gave the stock an "overweight" rating in a report on Tuesday, August 13th. UBS Group raised their price target on Guardant Health from $32.00 to $40.00 and gave the stock a "buy" rating in a report on Wednesday, August 21st. The Goldman Sachs Group raised their price target on Guardant Health from $32.00 to $36.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Finally, JPMorgan Chase & Co. raised their price target on Guardant Health from $48.00 to $50.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $40.60.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.